Blueprint Medicines Corporation (BPMC) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Cambridge, MA, 미국. 현재 CEO는 Kathryn Haviland.
BPMC 을(를) 보유 IPO 날짜 2015-04-30, 682 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $8.36B.
Blueprint Medicines Corporation is a precision therapy company that develops targeted medicines for genomically defined cancers and blood disorders globally. The company's marketed and pipeline products include AYVAKIT and BLU-263 for systemic mastocytosis and mast cell disorders, GAVRETO for RET fusion-positive cancers, Fisogatinib for hepatocellular carcinoma, and several investigational therapies targeting EGFR mutations in non-small-cell lung cancer, as well as rare genetic disorders. Blueprint maintains strategic collaborations with leading pharmaceutical partners including Genentech, Roche, CStone Pharmaceuticals, and Zai Lab to advance its precision medicine pipeline. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company is committed to delivering transformative treatments for patients with serious diseases driven by specific genetic alterations.
